S elective serotonin reuptake inhibitors (SSRIs) are among the most widely used drugs in psychiatry. SSRIs were initially developed as antidepressant drugs, but-in analogy with the widespread central functions of serotonin (5-hydroxytryptamine; 5-HT) (1)-they are nowadays used in the treatment of a variety of psychiatric conditions, including autism spectrum disorders, obsessive compulsive disorder, and eating disorders. Besides their wide application, their popularity is presumably related to their limited side effects and relative safety in adults. However, there are also drawbacks related to SSRI use. Patients experience clinical effects only after several weeks of treatment (2), there are substantial individual differences in the response to SSRIs (3), and early life exposure to SSRIs may lead to hazardous developmental outcomes (4). Despite extensive research, underlying mechanisms have not yet been clarified, which hampers the design of faster, more effective, and safer antidepressant drugs. In PNAS, a new mouse model is presented (5) that offers the possibility to come closer to a resolution of these major questions in the field. The unique knockin mouse bears a mutation in the serotonin transporter (SERT) gene that eliminates high-affinity recognition of a variety of SSRIs, as well as cocaine.The new transgenic mouse of Thompson et al. (5) carries a modified copy of SERT that bears a single amino acid substitution, I172 > M172, proximal to the 5-HT binding site. The M172 substitution significantly reduces the potency of SSRIs to (i) reduce SERT affinity and 5-HT reuptake in vitro, (ii) reduce the 5-HT 1A receptor-dependent firing rate of serotonergic raphe neurons, (iii) reduce 5-HT clearance in vivo, (iv) increase extracellular 5-HT levels in vivo, and (v) affect depression-related behavioral symptoms. Importantly, the amino acid substitution does not affect the recognition of 5-HT itself. As a consequence, the animals show a normal growth, basal SERT protein and forebrain/midbrain 5-HT, dopamine, and norepinephrine levels are unchanged, and the transgenic animals do not differ from I172 control mice for each of the five parameters assessing SERT function (Table 1). This new mouse model shows that SERT is the sole target of SSRIs and, thereby, has heuristic value for dissecting the role of SERT and altered 5-HT signaling in the in vivo actions of SSRIs, and other SERT inhibitors.What other SERT models have been generated thus far? First, we have the SERT knockout mice and rats (6). Because of the absence of SERT, SSRI recognition is lost and extracellular 5-HT levels are constitutively increased. Thereby, they could be viewed as animal models for chronic SSRI exposure. However, rather than showing low levels of anxiety-and depression-like symptoms, they show increases, which are hypothesized to be attributed to a variety of compensatory changes (Table 1). Indeed, 5-HT receptor expression, sensitivity, and/or function is altered, neuroplastic changes have been noted, and the animals show metabolic (inc...